Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

(Neutral)

(Positive)

Key Terms

amyotrophic lateral sclerosis medical

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

chronic traumatic encephalopathy medical

Chronic traumatic encephalopathy (CTE) is a progressive brain condition believed to be caused by repeated head impacts and concussions; think of it as long-term wear-and-tear on the brain that gradually affects mood, memory and thinking. It matters to investors because CTE can create legal liabilities, regulatory scrutiny, higher insurance costs and reputational damage for organizations linked to activities that produce repeated head trauma, which can affect cash flows and valuation.

t-cell medical

A T-cell is a type of immune cell that acts like a trained security guard, identifying and attacking infected or abnormal cells in the body. Investors care because many drugs and vaccines are designed to boost, redirect, or mimic T-cell activity; positive clinical results or regulatory approvals for T-cell–based therapies can drive significant changes in a company’s valuation, while safety or efficacy setbacks can hurt it.

treg medical

Treg, short for regulatory T cell, is a type of immune cell that acts like a brake on the immune system, calming or suppressing immune responses to prevent excessive inflammation or attack on the body's own tissues. For investors, therapies that boost or block Tregs can change the commercial outlook for drugs treating autoimmune diseases, organ transplant rejection or cancer, because shifting this balance can determine a treatment’s effectiveness and safety.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/15/2026 - 08:00 AM

Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT

Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 p.m. PT.

Titled ‘Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect’, the webinar will explore the relationship between repetitive head trauma, chronic inflammation, and neurodegenerative diseases, including chronic traumatic encephalopathy (CTE) and Amyotrophic lateral sclerosis (ALS), featuring insights from leaders in sports advocacy, clinical neurology, and therapeutic research.

Solomon Wilcots, NFL broadcaster and former player for the Cincinnati Bengals, will serve as the moderator for the webinar. He will be joined by the following participants:

Stanley H. Appel, M.D. – Edwards Distinguished Endowed Chair in ALS Research Professor, Stanley H. Appel Department of Neurology Houston Methodist Research Institute

Fred Grossman D.O. – President and Chief Medical Officer of Coya Therapeutics

Leigh Steinberg – Premier Sports Agent, Chairman, Steinberg Sports & Entertainment

Webinar Information

Pre-registration is now open HERE

Date: June 24, 2026

Time: 4 pm ET / 1 pm PT

Attendees may ask questions via written Q&A. A recording of the event will be posted to the Coya Therapeutics website.

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

For more information about Coya, please visit www.coyatherapeutics.com.